Skip to main content


Fig. 4 | Clinical Epigenetics

Fig. 4

From: Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer

Fig. 4

Combined APC/RASSF1A methylation and total plasma DNA assay was consistent with clinical judgment in ALC patients. a Patients with different methylation status and plasma DNA level had different tumor response and degrees of adverse events. The coincidence rates were  80.9, 84.6, 85.1, and 86.8 % in quadrants I to IV, respectively. bd Methylation status, plasma DNA level, and some clinical information of three patients in the validation model. b A male patient died within 5 months of diagnosis. c A female patient had been alive for 36 months by the end of follow-up. d A patient had been alive nearly 24 months by the end of follow-up

Back to article page